Spruce Biosciences
South San Francisco, CA · Biotechnology · 20 employees
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company aims to address significant unmet medical needs through innovative treatment solutions. Spruce has a particular focus on rare diseases and is committed to serving patient communities. They are known for their work in enzyme replacement
Funding history
- Venture - Series Unknown — $50.0M — Oct 2025
- Venture - Series Unknown — $53.6M — Feb 2023
- Venture - Series Unknown — $88.0M — Aug 2020
- Venture - Series Unknown — $88.0M — Feb 2020
- Series B — $88.0M — Feb 2020
Recent signals
- Jun 22, 2026: Spruce Biosciences Appoints Agnieszka Jurecka as Vice President of Medical Affairs
- Feb 03, 2026: Spruce Biosciences Appoints Daven Mody as Senior VP of Regulatory and Quality, Bruno Gagnon as Senior VP of Clinical Development Operations
- Oct 17, 2025: Raised $50.0M in Venture - Series Unknown
- Oct 15, 2025: SEC 8-K (5.02): On October 15, 2025, Dr. Bali Muralidhar resigned from his position as a member of the board of directors and the compensation committee of Spruce Biosciences, Inc. The resignation was effective immediately. Importantly, Dr. Muralidhar's departure was not due to any disagreements with the Company regarding its operations or policies. This change may impact the Board's dynamics and decision-making processes moving forward.
- Dec 30, 2024: Spruce Biosciences Appoints Kirk Ways as Interim Chief Medical Officer
- Feb 28, 2023: Raised $53.6M in Venture - Series Unknown
- Aug 14, 2020: Raised $88.0M in Venture - Series Unknown
- Feb 28, 2020: Raised $88.0M in Venture - Series Unknown
See plans & pricing → Track Spruce Biosciences’s funding, hiring, and signals — with verified contacts — on Fundz.